AU4663493A - Method for delivery of cytotoxic agents and components thereof - Google Patents

Method for delivery of cytotoxic agents and components thereof

Info

Publication number
AU4663493A
AU4663493A AU46634/93A AU4663493A AU4663493A AU 4663493 A AU4663493 A AU 4663493A AU 46634/93 A AU46634/93 A AU 46634/93A AU 4663493 A AU4663493 A AU 4663493A AU 4663493 A AU4663493 A AU 4663493A
Authority
AU
Australia
Prior art keywords
delivery
components
cytotoxic agents
cytotoxic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU46634/93A
Inventor
Victor J Chen
Louis N Jungheim
Damon L. Meyer
Timothy A Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of AU4663493A publication Critical patent/AU4663493A/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU46634/93A 1992-07-06 1993-07-02 Method for delivery of cytotoxic agents and components thereof Abandoned AU4663493A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US909924 1978-05-26
US90992492A 1992-07-06 1992-07-06
PCT/US1993/006324 WO1994001137A1 (en) 1992-07-06 1993-07-02 Method for delivery of cytotoxic agents and components thereof

Publications (1)

Publication Number Publication Date
AU4663493A true AU4663493A (en) 1994-01-31

Family

ID=25428053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46634/93A Abandoned AU4663493A (en) 1992-07-06 1993-07-02 Method for delivery of cytotoxic agents and components thereof

Country Status (6)

Country Link
CN (1) CN1087642A (en)
AU (1) AU4663493A (en)
IL (1) IL106228A0 (en)
MX (1) MX9304056A (en)
WO (1) WO1994001137A1 (en)
ZA (1) ZA934825B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025061A1 (en) * 1993-04-23 1994-11-10 Glyko, Inc. Methods and compositions for treating diseases with carbohydrate modifying enzymes
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
KR0185967B1 (en) * 1989-01-23 1999-05-01 에프. 쥐. 엠. 헤르만스; 에이. 쥐. 제이. 베르미렌 Site-specific in-vivo activation of therapeutic drugs
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof

Also Published As

Publication number Publication date
ZA934825B (en) 1995-01-05
IL106228A0 (en) 1993-11-15
MX9304056A (en) 1994-05-31
WO1994001137A1 (en) 1994-01-20
CN1087642A (en) 1994-06-08

Similar Documents

Publication Publication Date Title
AU4534593A (en) Compositions and methods for enhanced drug delivery
AU3201093A (en) Dental composition and method
AU5171293A (en) Ion-pairing of drugs for improved efficacy and delivery
AU8935591A (en) Drug delivery system and method
AU5358694A (en) Method and devices for delivering drugs by inhalation
AU3213193A (en) Method and apparatus for closed loop drug delivery
AU2259692A (en) Composition and method for transdermal delivery of diclofenac
AU1970495A (en) Drug delivery device and method of construction
EP0572932A3 (en) Method and implant device for long term delivery of drugs
AU678971B2 (en) Compositions and methods for vaccination against coronaviruses
IL107039A0 (en) Compositions comprising nomegestrol derivatives and processes for their production
IL107449A0 (en) Compositions and methods for reducing toxicity and increasing the efficacy of drugs
AU3406893A (en) Method and composition for the treatment of osteoporosis
AU3635693A (en) 1,4-dialkylpiperazine derivatives, method for obtaining them and pharmaceutical compositions containing them
AU3461095A (en) Compositions and methods for delivery of polypeptides
AU4520893A (en) Sterilization process and composition
AU1432292A (en) Drug delivery composition and method of using the same
AU3937693A (en) Methods and compositions for oral delivery of therapeutic agents
AU646649B2 (en) Method and apparatus for the aerosol administration of medication
AU2587195A (en) Growth hormone therapy and related methods and pharmaceutical compositions
AU3398793A (en) Anti-tumor method and anti-tumor agent
AU4663493A (en) Method for delivery of cytotoxic agents and components thereof
AU4104093A (en) Method and compositions for treatment of pyonecrotic processes
AU4571493A (en) Method and composition for controlling cockroaches
AU5657094A (en) Method and apparatus for spraying